Trusted by 100,000+ International Patients
Kidney Cancer Treatment: India vs Malaysia
Cost, Quality & Recovery Compared
$8000
India Starting Cost
$35000
Malaysia Starting Cost
See how these top medical tourism destinations compare for Kidney Cancer Treatment.
| Comparison Factor | India | Malaysia | Winner |
|---|---|---|---|
| Average Cost (in USD) | 8000 - 10000 | 35000 - 75000 | India |
| Success Rate (Min and Max) | 70% – 95% | 75% – 92% | Malaysia |
| Advanced Technology | Laparoscopic and robotic nephrectomy in tertiary centres, PET-CT/advanced imaging, pathology and molecular testing access, and targeted therapy/immunotherapy availability in major oncology hospitals. | Robotic and laparoscopic nephrectomy, high-resolution CT/MRI imaging, PET-CT, targeted therapy, and immunotherapy are available in leading oncology centres. | Both Equal |
| JCI Accredited Hospitals | 40+ | 10+ | India |
| Visa Process | Medical Visa (3–7 working days; extendable). | Medical Visa / eVisa / Tourist Visa (3–5 working days) | Both Equal |
*Costs are estimates and may vary based on hospital, complexity, and package inclusions. See detailed cost breakdown below
Understand exactly where your money goes. Both countries offer all-inclusive packages, but here's how the costs typically break down.
Best for Budget-Conscious Patients
Offered Package Price (Additional Cost Excluded)
Top Hospitals: BLK-Max Super Speciality Hospital , Shanti Mukand Hospital , Aster CMI Hospital , Fortis Hospital
Best for Flexible Donor Requirements
Offered Package Price (Additional Cost Excluded)
Want a personalized cost estimate based on your specific condition?
Get Your Free QuoteBoth India and Malaysia maintain world-class healthcare standards with internationally accredited hospitals and highly trained medical professionals.
40+ JCI-accredited hospitals; major cancer and urology centres also follow NABH-linked quality systems.
High-volume urology oncology centres follow NCCN/EAU-aligned care pathways; outcomes depend on stage and margin-negative resection.
Tertiary centres follow EAU/ESMO-aligned pathways with access to surgery and systemic therapy for advanced disease.
Many hospitals in Malaysia are accredited by the Joint Commission International (JCI) and the Malaysian Society for Quality in Health (MSQH), ensuring high standards of oncology care.
Cancer centres follow international oncology guidelines (NCCN, EAU), with outcomes depending on tumour stage, surgical technique, and systemic therapy.
Healthcare services are regulated by the Malaysian Ministry of Health (MOH), ensuring strict clinical safety, oncology protocols, and quality standards.
| Quality Metric | India | Malaysia |
|---|---|---|
Accredited Hospitals | 40+ | 10+ |
Minimally Invasive Nephrectomy Availability | Yes (tertiary centres) | Yes (major tertiary hospitals) |
Top Speciality Hospital Hubs | Delhi, Mumbai, Chennai | Kuala Lumpur, Penang, Johor Bahru |
Both countries have highly qualified and experienced medical specialists trained at premier institutions worldwide. Here's what sets them apart.
Uro-oncology surgeons
High surgical volumes in major metro cancer centres and tertiary urology hospitals.
Uro-oncology surgeons
Moderate to high volume
All surgeons listed on Medigence are verified for their medical license, board certifications, hospital affiliations, and patient outcomes. We conduct background checks and regularly update our database to ensure you're connected with the best medical professionals.
Beyond medical excellence, your comfort during treatment matters. Compare the patient experience at top hospitals in both destinations.
World-class hospitals, exceptional value
Leading hospitals in India offer advanced urology and oncology infrastructure, including robotic surgery systems, high-resolution imaging, modern operating theatres, oncology ICUs, and specialised pathology and radiology services for accurate diagnosis and treatment planning.
Luxury healthcare experience
Leading Malaysian hospitals offer advanced oncology infrastructure including robotic-assisted surgery (Da Vinci systems), modern operating theatres, PET-CT scanners, high-resolution CT/MRI imaging, dedicated oncology ICUs, and advanced pathology labs for precise diagnosis and personalised cancer treatment planning.
Plan your medical journey with confidence. Here's everything you need to know about travel, visas, and accommodation in both countries.
We provide end-to-end travel assistance including visa facilitation, airport pickups, hotel bookings near your hospital, and local support throughout your stay. Our patient coordinators handle all logistics so you can focus on recovery.
Understanding the recovery process helps you plan better. Here's what to expect after Kidney Cancer Treatment in both countries.
Kidney cancer treatment may involve partial or radical nephrectomy, depending on tumour size and location.
Patients are monitored in the ICU briefly after surgery if required.
Short local stay after discharge helps monitor wound healing and early recovery.
Gradual return to normal activities occurs with regular follow-up and medical guidance.
In-person follow-ups recommended at 3, 6, 12 months. Telemedicine available.
Kidney cancer treatment typically involves partial or radical nephrectomy depending on tumour characteristics.
Patients may require short ICU monitoring post-surgery.
International patients are advised to stay locally for early recovery and follow-up imaging.
Recovery improves gradually with regular monitoring and lifestyle adjustments.
Comprehensive telemedicine follow-up program. Return visits at 6, 12 months if possible.
Kidney Cancer Treatment recipients require lifelong immunosuppressant medications. Ensure you have a plan for obtaining these medications and regular blood monitoring in your home country before traveling abroad for surgery.
Every medical procedure carries risks. We believe in complete transparency so you can make a fully informed decision about your Kidney Cancer Treatment journey.
Surgery may carry risks of bleeding or infection at the surgical site.
Removal of a kidney may affect overall kidney function, requiring monitoring.
Patients may experience temporary pain, swelling, or fatigue during recovery.
Complications such as blood clots or urinary issues may occur in rare cases.
Targeted therapy or immunotherapy may cause fatigue, blood pressure changes, or immune-related effects.
The right choice depends on your specific situation. Here's a clear guide to help you decide which destination aligns with your needs.
Patients diagnosed with kidney cancer require surgical removal of the tumour or kidney, and those who may need additional treatments such as targeted therapy or immunotherapy, depending on disease stage.
Patients diagnosed with kidney cancer requiring tumour removal (partial or radical nephrectomy), with possible need for targeted therapy or immunotherapy based on cancer stage and progression.
Our medical tourism experts can analyze your case and recommend the best destination based on your medical history and budget.
Follow this step-by-step framework to make the right choice for your Kidney Cancer Treatment journey.
Consult a uro-oncologist to confirm a kidney cancer diagnosis and determine the stage of the disease.
Doctors review CT scans, MRI, and biopsy reports to decide between partial or radical nephrectomy and additional therapies.
Plan the budget for surgery, hospitalisation, medications, and follow-up care.
Provide imaging scans, pathology reports, and previous treatment history for accurate planning.
Regular follow-up imaging and blood tests are required to monitor recovery and detect recurrence early.
Let our medical tourism experts guide you through the process. We'll help you:
No obligation • Free consultation • Response within 24 hours
Surgical Oncologist
15 Years of Experience
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More
